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Abstract: Background. Human papillomavirus (HPV) has
been detected in keratinizing nasopharyngeal carcinomas
(NPCs); however, the relationship between HPV and Epstein–
Barr virus (EBV) among whites with nonkeratinizing NPCs
remains unclear. The HPV, p16, and EBV status was examined
in current University of Michigan patients with NPC.
Methods. From 2003 to 2007, 89 patients, 84 with oropha-
ryngeal cancer (OPC) and 5 with NPC, were enrolled in an
organ-sparing trial. Biopsy tissues from all 89 patients were
evaluated for HPV and p16 expression. A separate HPV analy-
sis of the 84 OPC patients is in progress. Among the patients
with NPC, tumor tissue was also analyzed for EBV-encoded
RNA (EBER).
Results. Five of 89 patients (5.6%) had NPC, all with non-
keratinizing histology. The 4 white patients with NPC
were HPV(þ) (subtype-16, subtype-18 [2 patients], and sub-
type-59)/p16(þ)/EBER(-). One Asian patient with NPC had an
HPV(-)/p16(-)/EBER(þ) NPC tumor that developed distant
metastases.
Conclusion. We postulate that HPV may be the etiologic fac-
tor in some EBV-negative, nonkeratinizing NPCs among whites.
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Nasopharyngeal carcinoma (NPC) is a rare dis-
ease in the United States, with an incidence rate of
less than 1 per 100,000.1–3 However, NPC occurs
muchmore frequently in certain parts of the world,
notably in Southern China with a reported inci-
dence of 15 to 30 per 100,000 among men and
women in Hong Kong.3 Interestingly, the incidence
of NPC remains higher among Chinese people who
immigrated to North America than Chinese people
who were born in North America.4 Thus, the etiol-
ogy of NPC is multifactorial, including environ-
mental factors, genetics, and infectious agents,
particularly the Epstein–Barr virus (EBV).1,3 In
the United States, the overall 5-year survival is
approximately 60%5 with an annually declining
mortality rate of 4.1%6 among whites. The reasons
for this decline in mortality are unclear, but may be
attributable to novel treatments or changes in the
etiology of NPC in the United States.
NPC is classified by the World Health Organi-
zation (WHO) according to histologic subtype.
Type I (WHO-I NPC) is characterized by kerati-
nizing, well-differentiated tumor cells; whereas
type II (WHO-II NPC) is characterized by nonker-
atinizing, differentiated tumor cells. Type III
(WHO-III NPC) denotes nonkeratinizing, undiffer-
entiated carcinoma (so-called lymphoepitheliomas)
and represents 63% to 95% of NPC tumors world-
wide.3 Some investigators have detected human
papillomavirus (HPV) in NPCs,7–10 particularly in
the keratinizing WHO-I NPC type.7,11,12 However,
the role of HPV in WHO-II and WHO-III NPC is
less understood. Although HPV is less commonly
found in WHO-II or WHO-III NPCs, coinfection
with HPV and EBV has been reported in these
nonkeratinizing NPC types.7–10 Isolated HPV
infection among EBV-negative nonkeratinizing,
WHO-II or WHO-III, NPC has not been reported
in the white North American populations.
Given the rarity of NPC in the United States,
there are few studies investigating its relationship
to HPV and EBV in this area.7,8 In patients from
the United States, HPV has been detected in up to
73% of those with tonsillar cancer13 and has been
implicated in the rising incidence of oropharyngeal
cancers.14–17 In a recent clinical trial for patients
with oropharyngeal cancers and NPC, all of the tu-
mor specimens were examined for the presence of
high-risk HPV. There were 5 patients with NPC
included in the trial. The purpose of this study was
to examine the HPV, p16, and EBV status among
all 5 patients with NPC included in this trial.
MATERIALS AND METHODS
Eighty-nine patients with previously untreated,
advanced (stage III and IV) oropharyngeal and
nasopharyngeal squamous cell carcinoma who
presented to the University of Michigan from
2003 through 2007 were enrolled in an organ-
sparing trial. All provided written informed con-
sent and participated in the University of Michi-
gan Head and Neck SPORE program which was
approved by the Institutional Review Board of
the University of Michigan. The patients were
treated with concomitant carboplatin, docetaxel,
and intensity-modulated radiation therapy
(IMRT). A tissue microarray (TMA) was con-
structed from pretreatment biopsies of primary
tumor sites for all 89 patients. All biopsies con-
tained sufficient tumor for a core sample to be
taken for DNA extraction and HPV analysis.
HPV type and copy number were assessed with a
sensitive, specific, quantitative method18 by Sen-
siGen LLC of Ann Arbor, MI. In brief, HPVanaly-
sis involved multiplex competitive polymerase
chain reaction and matrix-assisted laser desorp-
tion/ionization-time of flight mass spectroscopy
separation of products on a matrix-loaded silicon
chip array. This method uses primers designed to
amplify the E6 region to detect and quantify 15
high-risk HPV types 16, 18, 31, 33, 35, 39, 45, 51,
52, 56, 58, 59, 66, 68, and 73 as well as low-risk
types 6 and 11.18,19 A complete analysis of the
HPV-Positive, EBV-Negative NPC in Whites HEAD & NECK—DOI 10.1002/hed May 2010 563
HPV data and patient outcome for the 84 patients
with oropharyngeal cancer is in progress.
During analysis, it was determined that
among the 5 NPC patients, 4 were positive for
HPV. To follow up this observation, the charts of
these 5 patients were reviewed for date of initial
diagnosis, tumor stage, tumor location, WHO
grade, evidence of local recurrence, and distant
metastases through the most recent follow-up.
All 5 patients were confirmed to have primary
tumors originating high in the nasopharynx.
Tissue sections from the NPC patients were
analyzed in the pathology department for histol-
ogy and degree of differentiation, p16
(CDKN2A) expression by immunohistochemistry
and for EBV encoded RNA (EBER) using in situ
hybridization. In situ hybridization for EBER
(Ventana INFORM EBER, Tucson, AZ) was per-
formed on all cases according to the manufac-
turer’s protocol on the Bench–Mark automated
system.20 EBER staining was scored as positive
or negative. The CDKN2A protein, p16, is often
used as a surrogate for HPV infection because
the HPV oncoprotein, E7, binds to the retino-
blastoma protein releasing the transcription fac-
tor E2F which upregulates p16, leading to its
overexpression. P16 antibody (Biocare Medical,
Concord, CA; dilution 1:200) binding was scored
for proportion and intensity of tumor cell stain-
ing (cytoplasmic and nuclear) by a pathologist
(J.B.M.) on a scale of 1 to 4: 1 was less than 5%;
2, 5% to 20%; 3, 21% to 50%; and 4, 51% to
100% tumor staining. Intensity of p16 expres-
sion was scored as 1 equal to no staining; 2, low
intensity; 3, moderate; and 4, high intensity.
Proportion and intensity scores were added to
give a total staining score.
RESULTS
Of the 89 patients enrolled in the organ-sparing
trial, 75 (84.3%) were HPV-positive; of those, 65
(65/75; 86.7%) had HPV-16, 4 had HPV-18 (5.3%), 3
had HPV-35 (4%), and 1 had HPV-59 (1.3%). Of the
5 patients with NPC, 4 (80%) were HPV-positive.
This manuscript focuses only on those NPC cases.
The clinical characteristics of the 5 NPC patients
are depicted in Table 1. Among the 4 patients with
HPV-positive NPC, 1 had HPV-16, 2 had HPV-18,
and 1 had HPV-59 in their tumors (Table 1). All 4
HPV-positive NPCs stained positive (high intensity
and high proportion; total staining score ¼ 8) for
p16, and all 4 were negative for EBER (Figure 1).















1 White 58 T3N2cM0 II/NK SCC, differentiated Current/34 Positive/16 Positive Negative
2 White 75 T4N2cM0 III/NK SCC, undifferentiated Former pipe for 23 years Positive/18 Positive Negative
3 White 76 T4N0M0 III/NK SCC, undifferentiated Never/0 Positive/59 Positive Negative
4 White 58 T2bN2M0 II/NK SCC, differentiated Former/20 Positive/18 Positive Negative
5 Asian 50 T4N2cM1 III/NK SCC, undifferentiated Never/0 Negative Negative Positive
Abbreviations: WHO, World Health Organization; HPV, human papillomavirus; EBER, Epstein–Barr virus encoded RNA in situ hybridization; NK, non-
keratinizing; SCC, squamous cell carcinoma.
FIGURE 1. Histologic sections (400) of NPC tumors from
patients 1–5 (corresponds to Table 1). (Left panel) Hematoxylin-
Eosin (H&E)-stained sections. (Center panel) p16-stained sec-
tions. (Right panel) In situ hybridization for Epstein–Barr virus
encoded RNA (EBER).
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All of these 4 patients with HPV(þ)/p-16(þ)/
EBER(-) NPC were white North Americans. The
remaining patient with NPC was from Korea, and
her tumor tissue was negative for HPV and p16,
but positive for EBER (Table 1, Figure 1) and had
high EBV titers (1500 EBV DNA copies/mL
plasma) at the time of primary diagnosis (not
shown).
All 5 patients with NPC achieved an initial
complete response with carboplatin, docetaxel,
and concurrent IMRT. Referring to Table 1, the
HPV-16–positive patient with WHO-II NPC
(patient no. 1) recently developed recurrence at
the primary site after approximately 5 years
and is alive at 5.4 years following primary diag-
nosis. The HPV-18–positive patient with WHO-
III NPC (patient no. 2) is alive without disease
4.3 years after primary diagnosis. The patient
with HPV-59–positive WHO-III NPC (patient
no. 3) is alive without disease 5.8 years after
primary diagnosis. The other patient with HPV-
18–positive WHO-II NPC (patient no. 4) is also
alive without disease 1.4 years following pri-
mary diagnosis. The Asian patient with HPV(-)/
p16(-)/EBER(þ) WHO-III NPC (patient no. 5)
developed lung metastases after approximately
2 years (24.6 months) and was alive at last fol-
low-up 2.6 years after primary diagnosis.
DISCUSSION
The etiology of NPC in white populations
remains largely unknown. Although EBV is con-
sidered to be the primary etiologic factor for
NPC, particularly WHO-II and WHO-III dis-
ease, NPCs are occasionally EBV-negative.7–9
This has contributed to the investigation of
other potential etiologic agents for NPC, such as
HPV. The recent observation that oropharyngeal
cancers are frequently positive for HPV13,21,22 is
linked to the presence of lymphoid tissue at
these sites. Since HPV has a proclivity for the
epithelium overlying the lymphoid tissue of the
lower portions of Waldeyer’s ring, it is plausible
that the upper components of the ring—the fau-
cial tonsils and adenoids—also provide a site for
HPV-induced cancer of the nasopharynx.
To the best of our knowledge, this is the first
clinical report of HPV-positive/EBV-negative
NPCs of nonkeratinizing (WHO-II or WHO-III)
histologic subtype among white patients in the
United States. Two prior studies have investi-
gated NPC in patients from the United
States.7,8 One study by Punwaney et al7 investi-
gated HPV and EBV in NPCs from 7 North
American patients; 6 white Americans, and 1
Chinese American. They found that among the
6 white Americans, 4 had WHO-II or WHO-III
NPC, all of which were EBV-positive (2 were
coinfected with HPV and 2 were negative for
HPV). Among the 2 white Americans with kera-
tinizing (WHO-I) NPC, there was 1 HPV-posi-
tive/EBV-negative case. None of our patients
had WHO-I NPC; all 5 had WHO-II or WHO-III
NPC.
In another study by Rassekh et al8 from the
University of Texas, the HPV and EBV status of
17 patients (7 WHO-III and 10 WHO-I) was
investigated; however, the patients’ ethnicities
were not reported. Nine patients (9/17; 52.9%)
were HPV-positive—5 WHO-III patients and 4
WHO-I patients. All patients with HPV-positive
NPC were coinfected with EBV, including the 5
patients with HPV-positive WHO-III NPC.
Because of the high degree of HPV and EBV
coexistence among both keratinizing and non-
keratinizing NPC types, it was suggested
that EBV infection may facilitate HPV infec-
tion.8 This suggestion is not supported by our
results, given that there was no HPV and EBV
coinfection among the 5 NPC patients in our
cohort.
In fact, our limited results raise the possibil-
ity that HPV may act alone as an etiologic factor
in at least a subset of NPCs. However, given the
rare occurrence of NPC in our patient popula-
tion and in the United States as a whole, no de-
finitive conclusions about viral etiology can be
drawn from this report. For example, it cannot
be excluded that HPV could be a benign infec-
tion, noncontributory to the development or pro-
gression of NPC. Smoking is a possible etiologic
factor in 3 cases, but patient no. 3 and patient
no. 5 were never smokers. It could also be sug-
gested that these cases might be true oropha-
ryngeal neoplasms, misdiagnosed as NPC.
However, we reviewed the charts for every
patient and all had primary tumors originating
high in the nasopharynx; therefore, misdiagno-
sis is unlikely.
HPV-59 is genetically related to high-risk
HPV types 18 and 45. Although it is an uncom-
mon HPV type, it is categorized as high-risk, ie,
an oncogenic HPV type, along with HPV types
16, 18, 31, 45, and at least 9 other high-risk
types. A meta-analysis by Munoz et al23 pooled
data from 11 case-control studies involving
nearly 2000 women with SCC of the cervix and
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nearly 2000 control women. Based on its associ-
ation with cervical cancer, HPV-59 was identi-
fied as a high-risk HPV type. Furthermore,
HPV-59 isolated from a patient with condyloma
accuminata was shown to be capable of trans-
forming normal human foreskin keratinocytes
and producing virus in vitro.24 The transformed
cells eventually lost most of the episomal copies
and cells with approximately 2 copies of inte-
grated HPV-59 persisted.25 Because viral inte-
gration is a common finding in HPV-positive
human cancers, this observation further sup-
ports the assignment of HPV-59 to the high-
risk category. Of interest, patient no. 3 in our
cohort who was HPV-59 positive was a non-
smoker, leaving HPV-59 as a likely factor in his
disease.
The properties of HPV-positive oropharyn-
geal cancers that lead to high response to treat-
ment19 and good survival21 may similarly affect
the prognosis of patients with HPV-positive
NPC. The 4 patients with HPV-positive NPC in
our cohort had very advanced disease, yet all
responded well to treatment, although 1 had a
local recurrence at 5 years (patient no. 1). Of
note, this patient remained a current smoker.
The patient of Asian descent (patient no. 5) with
HPV(-)/p16(-)/EBER(þ) NPC developed distant
metastases after 2 years. The declining mortal-
ity rate from NPC among whites in the United
States,6 while not dramatic, is nonetheless
interesting. This could be due to advances in
treatment modalities, such as the use of IMRT,
or if HPV is an emerging etiologic factor in NPC
among whites, then these tumors as a group
may be more responsive to treatment than the
EBV-induced tumors.
Our data and other published studies7,8 raise
the hypothesis that HPV is a possible etiologic
factor in white North Americans who develop
NPC. Due to the relative paucity of NPC cases
at any one institution in the United States, it
would be of interest to carry out a multi-cen-
tered trial to determine the true incidence of
high-risk HPV involvement in this disease en-
tity. In a multi-centered trial it may be possible
to determine if HPV-induced NPC is more or
less responsive to current treatments than those
induced by EBV. Epidemiology studies would
also be of interest to determine if the incidence
of HPV-positive NPC is increasing in concert
with the increased frequency of HPV-positive
oropharyngeal cancers.
Note added in Proof: An additional white
male patient with advanced NPC presented to
our clinic since this paper was accepted for pub-
lication. This patient’s tumor is HPV(þ)/p16(þ)/
EBER(-), raising our total to 5 HPV(þ)/EBER(-)
NPC cases within the past 6 years.
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